Recent 8-K filings for AEMD

• July 7, 2026, 7:07 PM ET other material materiality 0.60 neutral item 1.01item 8.01item 9.01

  Aethlon Medical raises $4.0M in follow-on offering priced at $0.71/unit

  Gross proceeds of ~$4.0M from sale of common stock, pre-funded warrants, and warrants; net proceeds ~$3.335M.

• June 10, 2026, 4:15 PM ET earnings materiality 0.55 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Aethlon Medical reports FY2026 net loss $7.2M, cash $5.0M; oncology study enters final cohort

  Net loss $7.2M vs $13.4M prior year; operating expenses down 21.9% to $7.3M.

• June 4, 2026, 9:00 AM ET other material materiality 0.35 neutral item 8.01item 9.01

  Aethlon Medical files Amendment No. 1 to Prospectus Supplement; up to $542,716 remaining in ATM offering

  Filed Amendment No. 1 to Prospectus Supplement under S-3 Registration Statement (File No. 333-292405) on June 4, 2026.

• March 17, 2026, 7:59 PM ET other material materiality 0.30 neutral item 8.01

  Aethlon Medical discloses 1,569,110 shares outstanding after all pre-funded warrants exercised

  As of March 16, 2026, Aethlon Medical has 1,569,110 shares of common stock outstanding.

• February 23, 2026, 6:59 PM ET other material materiality 0.60 neutral item 5.02item 5.07item 5.03item 9.01 ◈ Governance Changes

  Aethlon Medical stockholders approve increase in authorized shares to 100M and equity plan amendment

  Stockholders approved increase in authorized common shares from 6M to 100M (495,950 for, 58,624 against).

• February 12, 2026, 6:59 PM ET earnings materiality 0.50 neutral item 2.02item 7.01item 9.01

  Aethlon Medical Q3 FY2026: cash $7.0M; operating loss $2.06M up 13.6% YoY

  Cash balance of ~$7.0M as of Dec 31, 2025; no revenue reported.

• January 26, 2026, 6:59 PM ET other material materiality 0.50 neutral item 1.01item 9.01 ◈ Material Agreements ×2

  Aethlon removes shareholder approval condition; pre-funded warrants immediately exercisable

  Amendments to SPA and Pre-Funded Warrant remove Nasdaq 5635 shareholder approval requirement, effective Jan 22, 2026.

• December 8, 2025, 6:59 PM ET other material materiality 0.65 neutral item 1.01item 3.03item 7.01item 9.01 ◈ Equity Issuances ×3◈ Material Agreements ×3

  Aethlon Medical prices $3.3M PIPE and warrant inducement at $4.03/unit

  Gross proceeds ~$3.3M from private placement and warrant inducement; closing expected Dec 8, 2025.

• November 12, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 7.01item 9.01

  Aethlon Medical Q2 fiscal 2025: operating loss narrows to $1.5M, clinical trial advances

  Cash balance $5.8M at Sept 30, 2025; operating expenses down 48% YoY to $1.5M.

• November 6, 2025, 6:59 PM ET regulatory materiality 0.60 positive item 8.01

  Aethlon Medical regains Nasdaq minimum bid price compliance, matter closed

  Received Nasdaq letter on Nov 5, 2025 confirming regained compliance with $1.00 minimum bid price rule.

• October 22, 2025, 7:59 PM ET regulatory materiality 0.80 negative item 3.01 ◈ Listing & Compliance Notices

  Aethlon Medical receives Nasdaq delisting notice for bid price below $1.00, requests hearing, implements reverse split

  Received Nasdaq notice on Oct 16, 2025 for non-compliance with minimum bid price of $1.00 over 30 consecutive business days.

• October 16, 2025, 7:59 PM ET other material materiality 0.75 neutral item 3.03item 5.03item 9.01 ◈ Governance Changes

  Aethlon Medical (AEMD) files 1-for-10 reverse stock split effective Oct 16, 2025; split-adjusted trading Oct 20

  Reverse split effective 10:00 a.m. ET Oct 16, 2025; split-adjusted trading begins Oct 20 under symbol AEMD.

• September 12, 2025, 7:59 PM ET other materiality 0.20 neutral item 8.01

  Aethlon Medical reports 7,373,156 shares outstanding after best-efforts offering

  Shares outstanding: 7,373,156 as of September 12, 2025.

• September 9, 2025, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 8.01item 9.01

  Aethlon Medical prices $4.5M public offering of common stock and warrants at $0.90/unit

  Gross proceeds of $4.5M; net to company ~$3.9M after placement agent fees and expenses.

• August 21, 2025, 7:59 PM ET other material materiality 0.25 neutral item 7.01item 9.01

  Aethlon Medical releases updated corporate presentation; no financial details disclosed

  Updated presentation furnished as Exhibit 99.1 and available on company website.

• August 13, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 7.01item 9.01

  Aethlon Medical reports Q1 FY2026 operating loss of $1.8M; cancer trial advances to second cohort

  Operating loss narrowed to $1.8M from $2.6M YoY; cash balance $3.8M at June 30, 2025.

• June 27, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 7.01item 9.01

  Aethlon Medical FY2025 op loss $9.3M (down 26% YoY); Hemopurifier cancer trial treats first 3 patients

  Cash balance $5.5M as of March 31, 2025; operating expenses $9.3M for FY2025, down 26% from $12.6M.

• June 5, 2025, 7:59 PM ET other material materiality 0.50 neutral item 8.01

  Aethlon Medical set 1-for-8 reverse stock split effective June 6, 2025

  Reverse split ratio: 1-for-8; effective 5:00 PM ET June 6, 2025.

• May 13, 2025, 7:59 PM ET other material materiality 0.55 neutral item 5.07

  Aethlon Medical stockholders approve reverse stock split authorization and warrant issuance at special meeting

  Stockholders approved reverse split at ratio 1:5 to 1:12, board to determine timing by May 13, 2026.

• March 17, 2025, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 3.02item 3.03item 9.01

  Aethlon Medical raises ~$2.3M via warrant exercise inducement, issues new warrants

  Gross proceeds of approximately $2,316,320 from exercise of 6,200,000 Existing Warrants at reduced price of $0.3736/share.

• February 12, 2025, 6:59 PM ET earnings materiality 0.55 neutral item 2.02item 7.01item 9.01

  Aethlon Medical Q3 net loss narrows to $1.8M; first patient treated in Hemopurifier cancer trial

  Cash balance $4.8M at Dec 31, 2024; operating expenses down 50% YoY to $1.8M.

• January 8, 2025, 6:59 PM ET other material materiality 0.55 neutral item 3.01 ◈ Listing & Compliance Notices ×2

  Aethlon Medical gets 180-day Nasdaq extension through June 23, 2025 for bid price rule

  Received 180-day extension from Nasdaq until June 23, 2025 to regain $1.00 minimum bid price compliance.

• December 20, 2024, 6:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  Aethlon Hemopurifier removes 99% of H5N1 in vitro; monitoring bird flu outbreak

  In vitro study with scaled-down Hemopurifier showed 99% removal of H5N1 virus after 6 hours.

• November 13, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 7.01item 9.01

  Aethlon Medical reports Q2 net loss $2.8M; enrolls first 2 patients in Hemopurifier cancer trial

  Net loss narrowed to $2.8M from $3.0M YoY; cash balance $6.9M as of Sep 30, 2024.

• November 12, 2024, 6:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Aethlon Medical enrolls first patient in Hemopurifier cancer trial for solid tumors

  First patient enrolled Oct 29, 2024 at Royal Adelaide Hospital; eligibility confirmed Nov 8.

• October 3, 2024, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 ◈ executive_change ×2

  Aethlon Medical appoints James B. Frakes as permanent CEO; COO Guy F. Cipriani departs

  James B. Frakes, serving as interim CEO since Nov 7, 2023, appointed permanent CEO effective Oct 3, 2024; remains CFO and Board member.

• October 2, 2024, 7:59 PM ET other material materiality 0.50 neutral item 5.02item 5.07item 9.01

  Aethlon Medical shareholders approve 3M share increase to 2020 Equity Plan; all director nominees elected

  Shareholders approved amendment to 2020 Equity Incentive Plan, increasing authorized shares by 3,000,000 to total 3,364,256 shares.

• September 19, 2024, 7:59 PM ET regulatory materiality 0.55 positive item 8.01item 9.01

  Aethlon receives ethics approval for Hemopurifier cancer trial in India; enrollment targeted Q4 2024

  Medanta Institutional Ethics Committee approved safety, feasibility, dose-finding trial of Hemopurifier in solid tumors not responding to anti-PD-1 antibodies.

• August 14, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01

  Aethlon Medical Q1 net loss $2.6M; cash $9.1M; ethics approvals for Hemopurifier trial

  Net loss $2.6M vs $3.3M YoY; operating expenses down 24% to $2.6M.

• August 12, 2024, 7:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Aethlon Medical receives second ethics approval for Hemopurifier cancer trial in Australia

  Bellberry Human Research Ethics Committee granted full ethics approval to Pindara Private Hospital for Hemopurifier trial in solid tumors not responding to anti-PD-1 antibodies.

• July 3, 2024, 7:59 PM ET other material materiality 0.55 neutral item 4.01item 9.01

  Aethlon Medical dismisses Baker Tilly, engages Haskell & White as new auditor

  Dismissed Baker Tilly US, LLP effective July 1, 2024; audit committee approved.

• June 27, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Aethlon Medical reports FY2024 net loss of $12.2M; cash at $9.1M; oncology trial approved

  Net loss of $12.2M for FY ended March 31, 2024, compared to $12.0M in FY2023.

• May 24, 2024, 7:59 PM ET other material materiality 0.30 neutral item 8.01

  Aethlon Medical reports 9,229,725 shares outstanding after public offering

  Outstanding shares as of May 23, 2024 total 9,229,725, updated after a best-efforts public offering.

• May 17, 2024, 7:59 PM ET other material materiality 0.70 neutral item 8.01item 9.01

  Aethlon Medical prices $4.7M public offering of common stock and warrants at $0.58 per unit

  Gross proceeds ~$4.7M; net proceeds ~$3.84M after placement agent fees and expenses.

• May 10, 2024, 7:59 PM ET other material materiality 0.40 positive item 8.01item 9.01

  Aethlon Medical reports positive in vitro Hemopurifier data for removing extracellular vesicles from cancer plasma

  In vitro binding study of Hemopurifier shows removal of extracellular vesicles (EVs) directly from cancer patient plasma.

• April 25, 2024, 7:59 PM ET other material materiality 0.10 neutral item 8.01item 9.01

  Aethlon Medical updates corporate presentation for April 2024; no material new details disclosed

  Updated presentation made available for investor meetings; filed as Exhibit 99.1.

• February 14, 2024, 6:59 PM ET earnings materiality 0.55 negative item 2.02item 9.01 ◈ Earnings Releases

  Aethlon Medical Q3 net loss widens to $3.6M; expenses up 25% on CEO separation costs

  Net loss of $3.6M for fiscal Q3 ended Dec 31, 2023, vs $2.8M a year ago.

• December 22, 2023, 6:59 PM ET leadership materiality 0.50 neutral item 5.02item 9.01 ◈ executive_change ×5

  Aethlon Medical sets compensation for Frakes as Interim CEO ($500K salary) and Cipriani as COO ($390K)

  James Frakes appointed Interim CEO effective Nov 7, 2023; base salary raised from $360K to $500K while in role.

• November 27, 2023, 6:59 PM ET leadership materiality 0.55 neutral item 5.02item 9.01 ◈ executive_change

  Dr. Charles Fisher resigns from Aethlon board Nov 27; $460k severance, 50% option acceleration

  Dr. Charles J. Fisher, Jr. resigns as director effective Nov 27, 2023; previously stepped down as CEO Nov 7.

• November 14, 2023, 6:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01 ◈ Earnings Releases

  Aethlon Medical reports Q2 net loss down to $3.0M; CEO Fisher replaced by Frakes

  Net loss for fiscal Q2 2023: $3.0M vs $3.8M in prior year; operating expenses decreased 13.4% to $3.2M.

• November 13, 2023, 6:59 PM ET leadership materiality 0.65 neutral item 5.02 ◈ executive_change ×5

  Aethlon Medical appoints James B. Frakes as Interim CEO; Charles J. Fisher Jr. departs

  Charles J. Fisher Jr., M.D. departed as CEO effective Nov 7, 2023; Guy F. Cipriani resigned as director.

• October 4, 2023, 7:59 PM ET other material materiality 0.55 neutral item 8.01item 9.01

  Aethlon completes 1-for-10 reverse stock split to maintain Nasdaq listing

  Reverse stock split approved by stockholders and board; ratio 1-for-10.

• September 18, 2023, 7:59 PM ET other material materiality 0.60 neutral item 5.07 ◈ Shareholder Votes ×2

  Aethlon Medical stockholders approve reverse stock split of 1:8 to 1:12

  Reverse stock split approved by 6,781,311 for, 2,180,424 against; Board to set ratio and effective date by Oct 5, 2023.

• August 10, 2023, 7:59 PM ET earnings materiality 0.50 negative item 2.02item 9.01 ◈ Earnings Releases

  Aethlon Medical Q1 FY2024 net loss $3.3M, cash $12.9M; Hemopurifier progress

  Net loss widened to $3.3M for quarter ended June 30, 2023 from $2.9M a year ago; operating expenses rose 17.3% to $3.4M.

• July 6, 2023, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

  Aethlon Medical appoints Nicolas Gikakis to Board of Directors

  Nicolas Gikakis appointed to Board and Nominating Committee effective July 3, 2023.

• June 28, 2023, 7:59 PM ET earnings materiality 0.50 neutral item 2.02item 9.01 ◈ Earnings Releases

  Aethlon Medical reports FY2023 cash $14.5M, operating expenses $12.47M; advances Hemopurifier trials

  Cash balance $14.5M at March 31, 2023; operating expenses $12.47M, up $1.76M from $10.71M in FY2022.

• April 25, 2023, 7:59 PM ET other material materiality 0.50 neutral item 8.01

  Aethlon Medical granted Nasdaq extension to Oct 23, 2023 to regain $1 bid price compliance

  Nasdaq approved extension request on April 25, 2023 after original deficiency notice on Oct 25, 2022.

• February 13, 2023, 6:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01 ◈ Earnings Releases

  Aethlon Medical reports Q3 net loss of $2.85M; cash $17.5M; hires Lee Arnold as CSO

  Net loss increased to ~$2.85M for quarter vs $2.53M year ago; operating expenses rose 12% to $2.85M.

• November 14, 2022, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Aethlon reports Q2 net loss $3.8M; terminates COVID trial, launches Australia sub

  Cash balance $19.6M as of Sep 30, 2022; operating expenses $3.67M, up 71% YoY.

• October 27, 2022, 7:59 PM ET regulatory materiality 0.65 negative item 3.01

  Aethlon Medical receives Nasdaq notice for non-compliance with $1.00 minimum bid price

  Common stock bid price closed below $1.00 for 30 consecutive trading days.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.55 · Most common event other_material

7 positive 4 negative 39 neutral

source · AEMD on sec.gov